Kidney International
Papers 21287
1 page of 2,129 pages (21.3k results)
#1Anne-Laure Faucon (French Institute of Health and Medical Research)H-Index: 1
#2Martin Flamant (French Institute of Health and Medical Research)H-Index: 21
Last.G. Guillaume (French Institute of Health and Medical Research)H-Index: 20
view all 10 authors...
Abstract Volume overload has been shown to be an independent risk factor for mortality in patients receiving chronic dialysis, but data in non-dialysis patients are scarce. Therefore we evaluated the prognostic value of extracellular fluid (ECF) volume for chronic kidney disease (CKD) progression and mortality in a prospective hospital-based cohort with CKD stage 1-4 (NephroTest Study). ECF (scaled to body surface area) and the measured glomerular filtration rate (mGFR) were determined using the...
#1Henning Trawinski (Leipzig University)
#2Thomas Karlas (Leipzig University)H-Index: 12
Last.Jan Halbritter (Leipzig University)H-Index: 21
view all 5 authors...
#1Kerstin Ebefors (University of Gothenburg)H-Index: 8
#2Robert J. Wiener (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
Last.Börje Haraldsson (University of Gothenburg)H-Index: 24
view all 10 authors...
Abstract Emerging evidence of crosstalk between glomerular cells in pathological settings provide opportunities for novel therapeutic discovery. Here we investigated underlying mechanisms of early events leading to filtration barrier defects of podocyte and glomerular endothelial cell crosstalk in the mouse models of primary podocytopathy (podocyte specific transforming growth factor-β receptor 1 signaling activation) or Adriamycin nephropathy. We found that glomerular endothelial surface layer ...
#1Natalia Alencar de Pinho (French Institute of Health and Medical Research)H-Index: 1
#2Adeera Levin (UBC: University of British Columbia)H-Index: 64
Last.Maarten W. Taal (University of Nottingham)H-Index: 1
view all 10 authors...
Although blood pressure (BP) control is a major goal in chronic kidney disease (CKD), no worldwide overview of either its achievement or antihypertensive prescriptions is currently available. To evaluate this we compared crude prevalence of uncontrolled BP among 17 cohort studies, including 34 602 individuals with estimated glomerular filtration rate under 60 ml/min/1.73 m2 and treated hypertension across four continents, and estimated observed to expected prevalence ratios, adjusted for potenti...
#1Rajiv Agarwal (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 62
Hypertension remains prevalent worldwide. In this commentary, the need for more effective treatment of this cardiovascular and renal risk factor is discussed. We can treat hypertension more effectively by getting the blood pressure measurement right, understanding the link between albuminuria and hypertension, enabling the use of spironolactone to treat resistant hypertension through the use of drugs that bind potassium in the gut, and addressing the structural determinants of health.
#1Manuela ColucciH-Index: 6
#2Rita CarsettiH-Index: 35
Last.Chiara GiannoneH-Index: 1
view all 10 authors...
The clinical heterogeneity of idiopathic nephrotic syndrome (INS) in childhood may reflect different mechanisms of disease that are as yet unclear. Here, we evaluated the association between an atypical presence of IgM on the surface of T cells (T-cell IgM) and the response to steroid therapy in a total of 153 pediatric patients with INS in different phases of disease. At disease onset, T-cell IgM median levels were significantly elevated and predictive of risk of relapse in 47 patients. They we...
#1Paola CassisH-Index: 18
#2Monica LocatelliH-Index: 9
Last.Ariela BenigniH-Index: 62
view all 10 authors...
The Renin-Angiotensin System (RAS) possesses a counter-regulatory axis composed of angiotensin I converting enzyme 2 (ACE)2, angiotensin-(1-7) [Ang-(1-7)] and the Mas receptor, which opposes many AT1-receptor–mediated effects of ligand angiotensin (Ang)II. Ang-(1-7), as a ligand of the Mas receptor, has inhibitory effects on renal inflammation and fibrosis in experimental diabetes. However, Ang-(1-7) has a short half-life in plasma, which may render it unsuitable for use in clinics. Here, we inv...
#1Alonso Marquez (NU: Northwestern University)H-Index: 1
#2Daniel BatlleH-Index: 44
In this commentary we emphasize the renoprotective effect of cyclic angiotensin-(1-7) described by Cassis et al. in a mouse model of diabetic kidney disease. The importance of the study is that this peptide was even more protective than the angiotensin-converting enzyme inhibitor lisinopril administered alone and that when the 2 componds were combined, the renoprotective action was additive.